title: [Inhibition effects of c-erbB-2 and c-raf-1 antisense oligodeoxynucleotides combined transfection on the human ovarian carcinoma transplanted subcutaneously in nude mice].
abstract: OBJECTIVE
  To investigate the inhibition effects of c-erbB-2 and c-raf-1 antisense oligodeoxynucleotides (ASODN) combined transfection on the human ovarian epithelial cancer transplanted subcutaneously in nude mice.
  
  
  METHODS
  There were 7 groups: normal control group, c-erbB-2 sense observed group, c-raf-1 sense observed group, c-erbB-2 antisense observed group, c-raf-1 antisense observed group, whole dose combined group, half dose combined group. Human ovarian epithelial cancer cells SKOV3 were treated by different oligodeoxynucleotides, then transplanted subcutaneously in nude mice, respectively. The changes of tumor volume were observed and the tumor growth inhibitory rate was calculated.
  
  
  RESULTS
  There was no difference between sense observed group and normal control group. There was a larger growth inhibitory rate in whole -dose combined group and half -dose combined group, the first time that can be detected was 13.7 days and 15.2 days, and the maximum tumor growth inhibitory rates were 61.1% and 71.3%, respectively.
  
  
  CONCLUSIONS
  The results suggested that ASODN combined transfection can inhibit the tumorigenesis of ovarian epithelial cancer cells in nude mice, it may be a more useful gene therapy for the ovarian epithelial carcinoma.
authors.affiliation: The First Affiliated Hospital, Chongqing Medical University, Chongqing 400016, China.
authors.forename: Yong-zhong
authors.initials: YZ
authors.lastname: Wu
authors.forename: Qing-lan
authors.initials: QL
authors.lastname: Ren
authors.forename: Su-fen
authors.initials: SF
authors.lastname: Yang
authors.forename: Xiao-pin
authors.initials: XP
authors.lastname: Chen
authors.forename: Shao-lin
authors.initials: SL
authors.lastname: Li
mesh_terms: D000818:Animals; D001835:Body Weight; D002455:Cell Division / Q000187:drug effects; D005260:Female; D015316:Genetic Therapy / Q000379:methods; D006801:Humans; D051379:Mice; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D016376:Oligonucleotides, Antisense / Q000235:genetics / Q000494:pharmacology*; D010051:Ovarian Neoplasms / Q000473:pathology*; D019908:Proto-Oncogene Proteins c-raf / Q000235:genetics*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics*; D014162:Transfection; D014183:Transplantation, Heterologous; D014407:Tumor Cells, Cultured
chemical_list: D016376:Oligonucleotides, Antisense; D019908:Proto-Oncogene Proteins c-raf; D018719:Erb-b2 Receptor Tyrosine Kinases